Biotheryx, Inc.

biotheryx, inc., founded by the drug development team behind the remarkable imids® franchise of compounds, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs. the identification of cereblon (an e3 ligase) as a key target of the imids® (the most successful class of anti-cancer drug in the world) showed that targeting protein degradation is a viable drug development strategy that can lead to enormous commercial success. with unmatched commercial and scientific experience, the biotheryx drug development team is building a set of high value assets in protein modulation known as protein homeostatic modulators or phms™. these novel small molecule cereblon binders have clinically relevant substrate degradation profiles that offer vast therapeutic opportunities. while phms™ have significant potential as novel small molecule therapeutics; they have a broad range of molecular orientations when bound to cereblon, providi